How Readmission Reduction Programs Keep Chronic Illness Patients Out of the Hospital

A patient gets discharged after a heart failure hospitalization. Twelve days later, she’s back in the emergency room with fluid buildup, labored breathing, and a blood pressure reading her care team never saw coming. The hospital stay was handled well. The discharge paperwork was complete. But between the moment she walked out the door and the moment she called 911, no one was watching.

This is the gap that a structured readmission reduction program is designed to close. The Hospital Readmissions Reduction Program, commonly called HRRP, is CMS’s primary financial mechanism for pushing hospitals to fix that gap. It ties Medicare inpatient payment rates to readmission performance, which gives it real leverage over clinical priorities. But the program’s deeper value is what it demands of hospitals: a fundamental redesign of care around what happens after discharge, not just during the stay.

A well-designed readmission reduction program closes that gap by providing continuous post-discharge monitoring and clinical escalation. RemoteHCS is built specifically to deliver that infrastructure for the Medicare-eligible, chronically ill patients HRRP targets most. Without clinical infrastructure that connects patients to their care teams between visits, readmission reduction strategies rest on a foundation with a missing floor. This article covers how HRRP works, how the penalty calculation functions in practice, what the research shows, and what the most effective readmission reduction programs look like when they’re built to last.

What the Hospital Readmissions Reduction Program Is and Why Hospitals Can’t Ignore It

The Policy Mandate and What’s at Stake Financially

HRRP was established under the Affordable Care Act and launched in fiscal year 2012. Its origin was straightforward: Medicare was paying billions annually for rehospitalizations that were, in many cases, preventable with better discharge planning and post-acute follow-up. The program created a direct financial consequence for hospitals with higher-than-expected readmission rates, attaching that consequence to Medicare inpatient payments across all admissions, not just the cases tied to the targeted conditions.

In fiscal year 2025, approximately 208 hospitals received Medicare readmission penalties of 1% or more, representing about 7% of hospitals in the program. The average penalty hovered around 0.3%, which sounds modest but compounds quickly at scale when applied to an entire year of Medicare inpatient revenue. For a hospital processing thousands of Medicare discharges annually, a fraction of a percentage point translates to a material dollar figure on the income statement.

Which Hospitals Are Required to Participate

Most general acute care hospitals paid under the Medicare inpatient prospective payment system (IPPS) are subject to HRRP. Critical access hospitals are exempt, as are certain specialty facilities, but the program covers the majority of U.S. hospitals that handle significant Medicare patient volumes. IPPS participation is the key threshold: a hospital paid under that system for inpatient Medicare claims will almost certainly fall within HRRP’s scope, which in practice means that the program applies broadly across community hospitals, academic medical centers, and regional health systems alike.

How HRRP Fits Inside the Larger Value-Based Purchasing Landscape

HRRP doesn’t operate in isolation. It sits alongside other CMS quality programs, including the Hospital Value-Based Purchasing Program and the Hospital-Acquired Condition Reduction Program, all of which tie hospital payment rates to clinical outcomes rather than volume. Together, these programs create a reimbursement environment where a hospital’s Medicare payment posture depends increasingly on quality metrics, not just throughput. Treating readmission reduction as a compliance checkbox misses the strategic reality: it’s one of several levers that collectively determine what Medicare pays that institution.

The Six Conditions HRRP Targets and What’s New Through 2026

The Current Six Covered Conditions

HRRP currently measures 30-day risk-standardized unplanned readmission rates for six specific conditions and procedures: acute myocardial infarction (AMI), heart failure (HF), chronic obstructive pulmonary disease (COPD), pneumonia, coronary artery bypass graft (CABG) surgery, and elective primary total hip and/or total knee arthroplasty (THA/TKA). These six were selected because they represent high-volume, high-cost diagnoses where post-discharge deterioration is common and often preventable. They also align with the conditions where multicomponent monitoring-driven intervention has the most established evidence base, which matters when building a response strategy.

The FY 2026 Performance Period and Upcoming FY 2027 Changes

For fiscal year 2026, CMS uses a performance period running from July 1, 2021 through June 30, 2024, with payment reductions effective October 1, 2025. The core set of six conditions remains unchanged for FY 2026. The significant methodological changes CMS finalized are set to take effect in FY 2027, and quality teams need to be preparing for them now.

For FY 2027, CMS is adding Medicare Advantage data across all six readmission measures, shortening the applicable performance period from three years to two, removing COVID-19 exclusions and related risk-adjustment elements, and extending the Extraordinary Circumstances Exception request window to 60 days. The Medicare Advantage data expansion carries the greatest operational significance: it will meaningfully alter how hospital performance is measured, particularly for institutions serving large MA populations who were previously invisible in the HRRP calculation.

How CMS Calculates the Excess Readmission Ratio and Converts It Into a Penalty

The Excess Readmission Ratio Formula, Explained Plainly

The excess readmission ratio (ERR) is the central calculation in HRRP. The formula is straightforward in concept: predicted readmissions divided by expected readmissions. Both figures come from hierarchical risk-adjusted statistical models that CMS runs using Medicare claims data. An ERR above 1.0 means a hospital had more readmissions than CMS predicted given its patient mix. An ERR of 1.0 or below means the hospital performed at or better than expected.

The phrase “risk-adjusted” does a lot of work here and deserves unpacking. CMS adjusts for patient age, sex, comorbidities, and prior-year clinical history when building its prediction models. What CMS does not adjust for is socioeconomic status, an omission that peer-reviewed analyses and CMS method critiques have flagged as one of the program’s most debated limitations. Hospitals serving low-income populations argue that patient poverty is a readmission driver that’s invisible in the ERR calculation, and the research broadly supports that concern.

From ERR to Payment Reduction: How the 3% Cap Works

CMS calculates a separate ERR for each of the six conditions. For any condition where a hospital’s ERR exceeds 1.0, those excess readmissions are weighted by the hospital’s Medicare discharge volume for that condition to produce a condition-level excess readmission payment figure. CMS then aggregates those figures across all applicable conditions and divides by the hospital’s total base operating DRG payments to produce a payment adjustment factor.

That adjustment factor is then applied to every Medicare inpatient claim the hospital submits during the fiscal year, capped at a maximum 3% reduction. To make the math concrete: if a hospital’s aggregate excess readmission payments represent 1.5% of its total base operating DRG payments, its payment adjustment factor reduces every Medicare inpatient claim by 1.5% for the year. The penalty isn’t applied only to heart failure or pneumonia claims, it comes off every Medicare inpatient payment. That’s the design feature that gives HRRP its financial reach.

What Exclusions and Risk Adjustments CMS Applies

CMS excludes several categories of discharges from readmission measurement to ensure comparability. Discharges against medical advice are excluded because the hospital didn’t have a full opportunity to complete care. Transfers to other acute care facilities are handled so only the receiving hospital’s admission counts as the index stay. Patients without continuous Medicare fee-for-service enrollment during the required lookback period are excluded because CMS can’t build a complete clinical history for risk adjustment.

Planned readmissions are also excluded from unplanned readmission measures, and this exclusion has direct operational implications. Hospitals that misclassify planned readmissions as unplanned will see their ERR inflated unnecessarily. CMS distinguishes planned from unplanned using a specific algorithm based on procedure codes and diagnosis codes, so accurate clinical documentation at discharge is one of the clearest ways to protect ERR from administrative errors rather than clinical failures.

Why Chronic Illness Patients Keep Ending Up Back in the Hospital

The Medication Gap That Opens at Discharge

Medication-related problems are among the most documented contributors to 30-day readmissions across virtually all HRRP-targeted conditions. When a heart failure patient leaves the hospital with an adjusted diuretic regimen, a new beta-blocker, and a discharge summary written at a 12th-grade reading level, the failure rate is predictable. Polypharmacy compounds the problem: patients managing four, six, or eight medications simultaneously face a daily adherence burden that discharge instructions alone can’t support.

The gap between hospital discharge and a patient’s first outpatient pharmacy fill is a particularly high-risk window. Many Medicare patients experience confusion during this period over which medications to continue, which are newly prescribed, and which to stop. Without active clinical support during that window to catch the confusion early, medication errors accumulate silently until they trigger a symptomatic crisis.

No One Monitoring the Patient Between Discharge and Follow-Up

The first seven to fourteen days after discharge, particularly the first seven, represent a high-risk period for readmission, a window supported by studies emphasizing the value of timely contact within seven days of discharge. This is when fluid is accumulating, blood pressure is drifting, or oxygen saturation is falling below safe thresholds, with no clinical team seeing any of it in real time. A post-discharge follow-up call at day seven is better than nothing, but it provides a single data point in a window that requires continuous observation for high-risk patients.

Without daily monitoring of vital signs, weight trends, or oxygen levels, clinical deterioration remains invisible until the patient is symptomatic enough to call for help. That’s the precise gap that remote monitoring infrastructure is designed to close, and it’s why ongoing physiological monitoring is a valuable component of evidence-supported readmission reduction programs, most consistently when it’s embedded in a broader multicomponent transitional-care bundle rather than deployed in isolation.

Fragmented Follow-Up and Care Coordination Failures

Patients discharged without a confirmed follow-up appointment are statistically more likely to return within 30 days. Patients whose primary care physicians don’t receive a timely discharge summary face the same risk, because the outpatient team is operating blind when that patient calls with a concern. Research on timely post-discharge follow-up consistently supports the value of contact within seven days for high-risk patients, particularly those with heart failure or COPD.

Care coordination failures at the handoff from inpatient to outpatient care are among the most modifiable readmission risk factors. The problem is that modification requires a designed process, not an assumed one. When discharge planning relies on patients to self-navigate the transition, the populations most at risk, older adults, those with cognitive limitations, and those with limited social support, are the ones most likely to fall through the gaps.

Building a Readmission Reduction Program That Lasts: The Three Core Components

Continuous Monitoring as a Central Component

Real-time physiological monitoring is the component that makes everything else more effective. A care coordinator can only intervene when they have data to react to. Without daily readings from connected devices, the transitional care infrastructure lacks an early warning system, it responds to patient-reported symptoms rather than clinical signals detected before a crisis. For HRRP-targeted conditions, the device types that matter most are blood pressure cuffs for hypertension and heart failure, pulse oximeters for COPD, and weight scales for tracking fluid retention in heart failure patients.

Daily readings transmitted to a licensed clinical team provide the kind of physiological visibility that post-discharge programs previously had no way to obtain outside an inpatient setting. A heart failure patient whose weight has increased three pounds over two days is showing a classic early warning sign of fluid overload. A care team that sees that trend on day four can intervene by day five. A care team that learns about it when the patient calls the ER has already lost the window.

Structured Follow-Up and Transitional Care Coordination

The Transitional Care Model developed by Mary Naylor and the Care Transitions Intervention developed by Eric Coleman are the two best-established transitional care frameworks in the Medicare evidence base. Both have demonstrated approximately 20% reductions in readmissions in randomized controlled trials, and both share a core design principle: the handoff from inpatient to outpatient care is a designed clinical process, not an administrative step. These models work because they assign an active care coordinator to bridge that handoff rather than leaving patients to navigate it alone.

Pre-discharge follow-up scheduling, timely communication of discharge summaries to outpatient physicians, and care transition coaching are the operational elements supported most consistently in the literature. The evidence for these interventions is strongest when they’re combined. A follow-up appointment delivered without a discharge summary creates a partial picture, just as a discharge summary sent without a scheduled appointment does, and either gap increases the risk of something falling through the cracks.

Medication Reconciliation and Adherence Support

Structured medication reconciliation at discharge compares the inpatient medication list against the patient’s pre-admission regimen and produces a clear, patient-facing list of what to take, what to stop, and what changed. When this process is led by a pharmacist and paired with patient education, the evidence supports meaningful reductions in medication-related revisits and adverse drug events. One five-hospital health system implementation of pharmacist-led discharge reconciliation reduced 30-day readmissions in high-risk patients from 17.5% to 15.5%. The caveat from systematic reviews is consistent: reconciliation alone, without education or follow-up, produces inconsistent benefit.

Post-discharge adherence support is where the impact extends beyond discharge day. Check-ins that catch missed doses, clinical alerts when patients report side effects, and refill reminders that close the gap between prescription and pharmacy pick-up are the tools that turn a discharge medication list into an actual adherence structure. For patients managing multiple chronic conditions simultaneously, this ongoing support bridges the gap between prescribing and real-world compliance.

What Outcomes Research Actually Shows About HRRP’s Real-World Impact

Where Readmission Rates Fell and by How Much

Multiple peer-reviewed analyses, including studies by Dharmarajan et al. and work cited in Joynt and Jha’s research on safety-net hospitals, found meaningful declines in 30-day readmissions for HRRP-targeted conditions, particularly AMI, heart failure, and pneumonia, following the program’s implementation in 2012. The association between HRRP’s introduction and falling readmission rates for these conditions is reasonably well-documented across several datasets and study designs. Whether the program caused those declines or captured a pre-existing trend is a question the literature doesn’t fully resolve, with some analyses attributing a meaningful portion of the reduction to improvement trajectories already underway before HRRP took effect.

The honest picture is that HRRP moved the needle for many hospitals, but not uniformly and not dramatically across every institution or patient population. At least one analysis found that safety-net and non-safety-net hospitals showed similar readmission changes, suggesting the program’s effects weren’t concentrated in one type of facility. What varies more than hospital type is the intensity of the intervention each institution deployed in response.

The Unresolved Mortality Question

The most important caveat in the HRRP research literature deserves direct attention. Several studies examining heart failure populations, including analyses published in JAMA Cardiology and the Journal of the American Heart Association, found that readmissions fell while short-term and longer-term mortality increased during the same period. The uncomfortable interpretation that follows: some patients who would previously have been readmitted may instead have died at home or been held in observation status, a category that doesn’t count as a readmission in HRRP measurement.

Other analyses found no material increase in mortality, and the conflict between these findings remains unresolved. What quality teams should take from this debate is a practical warning: optimizing for the 30-day readmission metric without simultaneously monitoring mortality rates and observation stay volumes can produce misleading performance signals. A falling readmission rate that coincides with rising post-discharge mortality isn’t an improvement, it’s a data artifact that obscures a patient safety problem.

What the Evidence Says About Which Programs Actually Reduce Risk

The operational takeaway from the outcomes literature is clear even where the mortality question is not: multicomponent interventions consistently outperform single-strategy approaches. Programs that combine discharge planning, transitional care coordination, medication reconciliation, and post-discharge monitoring show stronger readmission reduction than any individual element deployed alone. This finding holds across systematic reviews, meta-analyses, and implementation evaluations spanning more than a decade of HRRP experience.

The implication for hospital quality teams is direct: there is no single fix for 30-day readmissions. A hospital that builds a strong discharge checklist but doesn’t monitor patients after they leave has addressed the wrong half of the problem. The monitoring infrastructure that connects discharged patients to their clinical teams is the component that makes everything else work, provided it’s paired with the coordination and reconciliation elements that the evidence supports.

How a Readmission Reduction Program Uses Remote Patient Monitoring as Its Infrastructure

The Monitoring Gap That Traditional Discharge Programs Can’t Close

Most transitional care programs and readmission reduction initiatives were designed before connected device infrastructure became clinically accessible at scale or Medicare-reimbursable under CMS billing codes. The result is programs built on phone calls, scheduled follow-up visits, and discharge checklists, all of which are valuable, but none of which provide real-time physiological data. A care coordinator who calls a heart failure patient at day seven but has no weight or blood pressure readings from days one through six is working with a fraction of the clinical picture that’s actually available.

The monitoring gap isn’t a design failure by the people who built those programs, it’s a technology timing problem. That infrastructure now exists and is reimbursable through Medicare. It’s worth noting that the evidence on remote physiological monitoring is nuanced: heart failure RCTs have produced mixed results, with several showing null effects for RPM as a standalone intervention, while some COPD telemonitoring syntheses suggest possible reductions with lower certainty. The stronger signal in the literature is for RPM embedded within broader multicomponent bundles, which is precisely how a well-structured readmission reduction program should deploy it. The practical question for hospital quality teams is whether the monitoring program they implement includes the clinical oversight layer that turns data into action.

How RemoteHCS Provides the Monitoring Backbone These Programs Need

RemoteHCS is designed for this gap. The platform provides HIPAA-compliant connected devices, daily vital sign transmission, licensed clinician oversight, and clinical escalation protocols for the chronic conditions that HRRP targets most directly, heart failure, COPD, hypertension, and pneumonia recovery, among others. Unlike general telehealth platforms structured around on-demand urgent care, RemoteHCS is built around ongoing, condition-specific chronic care between visits, which is the use case a readmission reduction program actually requires.

RPM services are covered through CMS for Medicare-eligible patients, which removes the sustainability barrier that limits many hospital-based readmission reduction programs to grant-funded pilot phases. A monitoring program built on reimbursable infrastructure can outlast any single funding cycle and become a permanent part of the post-discharge care model rather than a time-limited initiative.

The Clinical Oversight Layer That Makes Monitoring Actionable

Devices don’t reduce readmissions. Licensed clinicians who respond to the data those devices transmit are what reduces readmissions. RemoteHCS provides that clinical oversight layer as a core part of its model. Licensed clinicians review daily readings from enrolled patients, identify deterioration signals before they become emergencies, and coordinate directly with the patient’s existing care team when escalation is needed.

This is the loop that most readmission reduction programs struggle to close operationally: the connection between physiological data and clinical action. A hospital can discharge a patient with a connected blood pressure cuff and a smartphone app, but if no licensed clinician is reviewing that data daily and responding to concerning trends, the monitoring amounts to surveillance without follow-through. RemoteHCS closes that loop by design, functioning as a clinical service that happens to use technology, not a technology product that hospitals are left to staff and interpret themselves.

Building a Readmission Reduction Strategy That Holds Up Under Scrutiny

Start With Your Highest-Risk Populations and HRRP-Targeted Conditions

An effective readmission reduction program starts with prioritization. Heart failure, COPD, and pneumonia carry the highest readmission rates among HRRP-targeted conditions and also have the most established evidence base for monitoring-driven intervention within multicomponent bundles. These are the populations where intensive post-discharge monitoring delivers the clearest clinical return and where the financial exposure from HRRP penalties is typically largest.

Within those condition groups, risk stratification helps allocate monitoring resources toward the patients who need them most. Patients with prior hospitalizations in the last 12 months, those managing multiple chronic conditions simultaneously, those with documented low medication adherence, and those with limited social support at home are the highest-priority targets for intensive post-discharge enrollment. A structured risk stratification process built into the discharge workflow, rather than applied retrospectively, ensures that monitoring capacity reaches the patients who will benefit most from it.

The KPIs Worth Tracking Beyond the 30-Day Rate

The 30-day readmission rate is the headline metric, but it doesn’t tell a complete story. A hospital that successfully drives down readmissions while observation stay rates climb, or while post-discharge mortality rises, hasn’t improved patient outcomes, it has shifted where those outcomes occur. Tracking the right set of supporting metrics protects against that kind of distortion.

The most informative set of KPIs for a readmission reduction program includes:

• 7-day readmission rate (the highest-risk early window)
• Observation stay rates for HRRP-targeted conditions
• Post-discharge 30-day mortality rate
• Days to first post-discharge follow-up appointment
• Medication adherence rates among enrolled patients
• RPM enrollment rates among Medicare-eligible discharges for targeted conditions

Tracking observation stays alongside readmissions is particularly important given the mortality research. If the readmission rate is falling while observation admissions for the same conditions are rising, that’s a signal worth investigating before the next HRRP performance period closes.

Making Post-Discharge Monitoring Sustainable and Reimbursable

Medicare covers RPM services through a set of CPT codes that most quality teams aren’t fully leveraging. CPT 99453 covers device setup and patient education. CPT 99454 covers the monthly device supply and data transmission. CPT 99457 covers the first 20 minutes of monthly clinical staff time reviewing data and communicating with the patient. CPT 99458 covers each additional 20-minute increment of monthly clinical review time. Together, these codes create a reimbursement pathway that makes daily monitoring financially sustainable for Medicare-eligible patients without relying on hospital grants or pilot funding.

A readmission reduction program built on this reimbursement framework can sustain itself past the grant funding phase and the first pilot cohort. It becomes a durable clinical service rather than a time-limited intervention, which is the only version of a readmission reduction program that actually changes a hospital’s HRRP trajectory across multiple performance periods. The infrastructure investment is the work. The reimbursement framework is what makes that investment hold.

The Infrastructure Question Is the One Worth Solving Now

The HRRP is not going away, and its scope is expanding. Medicare Advantage data enters the calculation in FY 2027. The performance period is shortening. Hospitals that have been managing their ERR on the margins will have less room to absorb those changes without operational adjustments. The institutions making the most consistent progress are those that stopped treating post-discharge monitoring as an administrative function and built it into their clinical infrastructure.

The excess readmission ratio will keep calculating. Medicare readmission penalties will keep applying. What determines a hospital’s trajectory under those conditions is whether care teams have the real-time data and clinical capacity to intervene before a patient deteriorates enough to return. For chronic illness patients who need daily monitoring between visits, not just a follow-up call at day seven, that infrastructure is the difference between a readmission that was preventable and one that wasn’t caught in time.

If you’re building or refining a readmission reduction program, the monitoring infrastructure question is the one worth solving before the next performance period closes. RemoteHCS is designed to provide exactly that infrastructure for the Medicare-eligible, chronically ill patients who drive HRRP exposure most. Enrollment is open for patients across all 50 states, the clinical framework is in place, and the path to closing the post-discharge gap is a concrete operational decision, not a distant one.